[go: up one dir, main page]

CR9579A - Inhibidores de tirosina quinasa - Google Patents

Inhibidores de tirosina quinasa

Info

Publication number
CR9579A
CR9579A CR9579A CR9579A CR9579A CR 9579 A CR9579 A CR 9579A CR 9579 A CR9579 A CR 9579A CR 9579 A CR9579 A CR 9579A CR 9579 A CR9579 A CR 9579A
Authority
CR
Costa Rica
Prior art keywords
kinase inhibitors
relates
thyrosine kinase
thyrosine
met
Prior art date
Application number
CR9579A
Other languages
English (en)
Inventor
J Disnmore Christopher
P Jewell James
D Katz Jason
R Machacek Michelle
D Otte Ryan
R Young Jonathan
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CR9579A publication Critical patent/CR9579A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a derivados de 5H-benzo(4,5) ciclohepta(1,2-b) piridina, que son utiles para tratar enfermedades proliferaivas celulares, para tratar transtornos asociados con actividad de MET, y para inhibir la tirosina quinasa de receptor MET. La invencion tambien se refiere a composiciones que comprenden estos compuestos, y a procedimientos para usarlos para tratar el cancer en mamiferos.
CR9579A 2005-06-23 2007-12-07 Inhibidores de tirosina quinasa CR9579A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69322905P 2005-06-23 2005-06-23
US72906105P 2005-10-21 2005-10-21
US78947306P 2006-04-05 2006-04-05

Publications (1)

Publication Number Publication Date
CR9579A true CR9579A (es) 2008-03-06

Family

ID=37595817

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9579A CR9579A (es) 2005-06-23 2007-12-07 Inhibidores de tirosina quinasa

Country Status (21)

Country Link
EP (1) EP1896422B1 (es)
KR (1) KR20080018907A (es)
AR (1) AR057377A1 (es)
AT (1) ATE520664T1 (es)
BR (1) BRPI0612518A2 (es)
CR (1) CR9579A (es)
CY (1) CY1112038T1 (es)
DO (1) DOP2006000143A (es)
EC (1) ECSP078017A (es)
IL (1) IL187895A0 (es)
MA (1) MA29643B1 (es)
MX (1) MX2007016533A (es)
NI (1) NI200700318A (es)
NO (1) NO20080417L (es)
NZ (1) NZ563711A (es)
PE (1) PE20070167A1 (es)
PL (1) PL1896422T3 (es)
PT (1) PT1896422E (es)
SI (1) SI1896422T1 (es)
TW (1) TW200738638A (es)
WO (1) WO2007002258A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813021A (en) * 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
US7893081B2 (en) * 2007-12-20 2011-02-22 Merck & Co., Inc. Tyrosine kinase inhibitors
EP2482803B1 (en) 2009-09-30 2021-12-22 Merck Sharp & Dohme (UK) Limited Formulations for c-met kinase inhibitors
CA2771338A1 (en) 2009-09-30 2011-04-07 Merck Sharp & Dohme Corp. Crystalline hydrochloride salts of c-met kinase inhibitors
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE363473T1 (de) * 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
WO2003084931A1 (en) * 2002-04-02 2003-10-16 Merck & Co., Inc. 5h-benzo[4,5]cyclohepta[1,2-b]pyridine nmda/nr2b antagonists

Also Published As

Publication number Publication date
AR057377A1 (es) 2007-11-28
PL1896422T3 (pl) 2012-01-31
CY1112038T1 (el) 2015-11-04
EP1896422B1 (en) 2011-08-17
BRPI0612518A2 (pt) 2010-11-23
ATE520664T1 (de) 2011-09-15
MA29643B1 (fr) 2008-07-01
NZ563711A (en) 2010-12-24
EP1896422A2 (en) 2008-03-12
WO2007002258A2 (en) 2007-01-04
PE20070167A1 (es) 2007-04-16
IL187895A0 (en) 2008-03-20
ECSP078017A (es) 2008-01-23
NI200700318A (es) 2008-05-23
MX2007016533A (es) 2008-03-06
KR20080018907A (ko) 2008-02-28
PT1896422E (pt) 2011-11-08
SI1896422T1 (sl) 2011-11-30
NO20080417L (no) 2008-03-18
DOP2006000143A (es) 2007-02-28
WO2007002258A3 (en) 2007-06-07
TW200738638A (en) 2007-10-16

Similar Documents

Publication Publication Date Title
CR10560A (es) Inhibidores de tirosina quinasa
CR9579A (es) Inhibidores de tirosina quinasa
DK1896421T3 (da) Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
WO2007149427A3 (en) Tyrosine kinase inhibitors
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
ECSP12008540A (es) PIRROL[2,3-b]PIRIDINAS Y PIRROL[2,3-b]PIRIMIDINAS HETEROARILO SUSTITUIDAS COMO INHIBIDORES DE QUINASAS JANUS
GT200500198A (es) Nuevos derivados piperidilo de quinazolina e isoquinazolina
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
EP1515724A4 (en) MITOTIC KINESINE HEMMER
EP1463733A4 (en) INHIBITORS OF MITOTIC KINESINE
ECSP066362A (es) Inhibidores de quinesina mitótica.
PA8624101A1 (es) Derivados de tetrahidroisoquinolinilo de quinazolina e isoquinolina
ECSP088121A (es) Derivados de pirrolo [2,3-b] piridina comoinhibidores de proteina cinasa
WO2006124354A3 (en) Tyrosine kinase inhibitors
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
NO20070589L (no) Mitotiske kinesin-inhibitorer.
WO2006086358A3 (en) Mitotic kinesin inhibitors
WO2007050380A3 (en) Tyrosine kinase inhibitors
WO2006078598A3 (en) Mitotic kinesin inhibitors
EP1635641A4 (en) INHIBITORS OF MITOTIC KINESINE
WO2007050383A3 (en) Tyrosine kinase inhibitors
WO2007050401A3 (en) Tyrosine kinase inhibitors
DOP2009000004A (es) Inhibidores de tirosina quinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)